

76. The antibody or antigen-binding fragment of Claim 38 wherein said antibody or fragment is a humanized or chimeric antibody or a humanized or chimeric antigen-binding fragment.
77. The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11, and wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
78. The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11, and wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
79. The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2, and is a humanized immunoglobulin or antigen-binding fragment comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 and a human framework region.
80. The antibody or antigen-binding fragment of Claim 70 wherein said antibody or fragment can compete with monoclonal antibody 7B11 for binding to a human C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4, and is a humanized immunoglobulin or antigen-binding fragment comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 and a human framework region.